There was a similar issue with Wellbutrin extended, where the active ingredient was theoretically the same, but the bit that was supposed to slowly give it to y

There was a similar issue with Wellbutrin extended, where the active ingredient was theoretically the same, but the bit that was supposed to slowly give it to you would dump it on you instead. "'In the first two hours of a dissolution test, we found Budeprion released 34 percent of the drug, while Wellbutrin released 8 percent. At four hours, the Teva product released nearly half of its ingredients, while original Wellbutrin released 25 percent. The generic did not act like a once-a-day formula but more like an immediate release formula,' Dr. Todd Cooperman, Consumer Lab's president, stated." https://abcnews.go.com/Health/fda-finds-generic-antidepressant-original/story?id=17399399 https://abcnews.go.com/Health/fda-finds-generic-antidepressa... https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/update-bupropion-hydrochloride-extended-release-300-mg-bioequivalence-studies https://www.fda.gov/drugs/postmarket-drug-safety-information... Problem with that is Wellbutrin can cause seizures if you have too much at once, and it synergizes with things like ADHD meds to lower the seizure threshold further. Since Wellbutrin itself is a third-line ADHD medication, that last bit was a real issue--at one point I was prescribed both Wellbutrin XL -and- Concerta, and had to get "only as prescribed" scrips for both to avoid generics. Pulling the Wellbutrin generic with the known-bad delivery mechanism was one of the few cases where the FDA actually stepped in on a previously-approved generic and did something. In general, I don't worry too much about the active ingredients in generics (though maybe I should) but I worry an awful lot about extended-delivery mechanisms. I don't think testing or standards are sufficient to enforce a bioavailability curve across a dosage lifetime.